[go: up one dir, main page]

CY1109906T1 - Παραγωγα c3-kyano εποθιλονης - Google Patents

Παραγωγα c3-kyano εποθιλονης

Info

Publication number
CY1109906T1
CY1109906T1 CY20101100251T CY101100251T CY1109906T1 CY 1109906 T1 CY1109906 T1 CY 1109906T1 CY 20101100251 T CY20101100251 T CY 20101100251T CY 101100251 T CY101100251 T CY 101100251T CY 1109906 T1 CY1109906 T1 CY 1109906T1
Authority
CY
Cyprus
Prior art keywords
kyano
producer
copper
cancer
treatment
Prior art date
Application number
CY20101100251T
Other languages
English (en)
Inventor
Alicia Regueiro-Ren
Soong-Hoon Kim
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1109906T1 publication Critical patent/CY1109906T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Pencils And Projecting And Retracting Systems Therefor, And Multi-System Writing Instruments (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ενώσεις που χρησιμεύουν στην αντιμετώπιση του καρκίνου ή άλλων πολλαπλασιαστικών παθήσεων, οι οποίες αντιπροσωπεύονται από τον χημικό τύπο I: (Χημικός τύπος I)- όπου: το Q επιλέγεται από την ομάδα που αποτελείται από: (Χημικός τύπος II)· το Μ είναι Ο, NR9 ή CR10R11 το Χ είναι Ο ή ΝΗ· και οι ομάδες R είναι όπως αυτές έχουν οριστεί, ενώ οι φαρμακευτικές συνθέσεις που τις περιέχουν είτε μόνες τους είτε σε συνδυασμό με άλλους θεραπευτικούς παράγοντες, χρησιμεύουν στην αγωγή του καρκίνου ή άλλων πολλαπλασιαστικών παθήσεων.
CY20101100251T 2002-03-12 2010-03-19 Παραγωγα c3-kyano εποθιλονης CY1109906T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36344102P 2002-03-12 2002-03-12
EP03714096A EP1483251B1 (en) 2002-03-12 2003-03-11 C3-cyano epothilone derivatives

Publications (1)

Publication Number Publication Date
CY1109906T1 true CY1109906T1 (el) 2014-09-10

Family

ID=28041767

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100251T CY1109906T1 (el) 2002-03-12 2010-03-19 Παραγωγα c3-kyano εποθιλονης

Country Status (11)

Country Link
US (1) US6719540B2 (el)
EP (1) EP1483251B1 (el)
AT (1) ATE452896T1 (el)
AU (1) AU2003218110A1 (el)
CY (1) CY1109906T1 (el)
DE (1) DE60330651D1 (el)
DK (1) DK1483251T3 (el)
ES (1) ES2337134T3 (el)
PT (1) PT1483251E (el)
SI (1) SI1483251T1 (el)
WO (1) WO2003078411A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE10355223A1 (de) 2003-11-26 2005-06-30 Institut für Pflanzenbiochemie (IPB) Neue Makrocyclen zur Behandlung von Krebserkrankungen
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
DE602005007376D1 (de) * 2004-11-18 2008-07-17 Bristol Myers Squibb Co Magensaftresistent beschichtetes pellet mit ixabepilon
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
CA2647565A1 (en) 2006-03-31 2007-10-18 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
CN104116736A (zh) * 2008-04-24 2014-10-29 百时美施贵宝公司 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN105797168A (zh) 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
WO2015107534A1 (en) * 2013-11-04 2015-07-23 Emcure Pharmaceuticals Limited Lyophilized formulation of treosulfan

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272525A (en) 1978-10-23 1981-06-09 Schering Corporation Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them
US4820695A (en) 1982-09-13 1989-04-11 Eli Lilly And Company C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
US5217960A (en) 1991-05-03 1993-06-08 Abbott Laboratories Erythromycin derivatives
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
TW226373B (el) 1992-07-15 1994-07-11 Pfizer
US5677287A (en) 1993-03-18 1997-10-14 Pfizer Inc. Antibacterial 16-membered ring macrolides containing olefins at C-20
CA2167201A1 (en) 1993-07-15 1995-01-26 Kristin M. Lundy Amide derivatives of 16-membered ring antibiotic macrolides
SG49853A1 (en) 1993-08-16 2001-07-24 Novartis Ag Novel macrolides and the use thereof
AU3121095A (en) 1994-09-22 1996-04-09 Pfizer Inc. Antibiotic macrolides
IL117200A0 (en) 1995-02-21 1996-06-18 Schering Ag Diethylenetriamine-pentaacetic acid monoamide derivatives pharmaceutical compostions containing the same and processes for the preparation thereof
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
EP1186606B2 (de) 1995-11-17 2011-09-07 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate, ihre Herstellung und Verwendung
EP0778283A3 (en) 1995-12-05 1998-01-28 Pfizer Inc. Antibiotic macrolides
DE19613933A1 (de) 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US6174434B1 (en) 1996-04-26 2001-01-16 The Lenox Institute Of Water Technology, Inc. Three zone dissolved air floatation clarifier with fixed lamellae and improved paddle-and-ramp sludge removal system
WO1998002460A1 (en) 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
GB9615498D0 (en) 1996-07-24 1996-09-04 Ciba Geigy Ag Kinase
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
EA001913B1 (ru) 1996-08-30 2001-10-22 Эли Лилли Энд Компани Фармацевтические соединения
PT1367057E (pt) 1996-11-18 2008-12-04 Biotechnolog Forschung Gmbh Epotilonas e e f
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CN1128803C (zh) 1997-02-25 2003-11-26 生物技术研究有限公司(Gbf) 环氧噻嗪酮b－n－氧化物及其制备方法
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
US6140051A (en) 1997-07-21 2000-10-31 Promega Biosciences, Inc. Fluorescent dibenzazole derivatives and methods related thereto
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
AU9537298A (en) 1997-09-08 1999-03-29 Novartis Ag Heterocyclic compounds as pesticides
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6090601A (en) 1998-01-23 2000-07-18 Kosan Bioscience Sorangium polyketide synthase
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
EP0948967B1 (en) 1998-03-02 2004-11-03 Eli Lilly And Company Treatment of viral disease in swine
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
EP1082439A2 (en) 1998-05-28 2001-03-14 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
NZ508326A (en) 1998-06-18 2003-10-31 Novartis Ag A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
AU768751B2 (en) 1998-06-18 2004-01-08 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
WO2000001701A1 (en) 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000001702A1 (en) 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE19848306A1 (de) 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
AU758421B2 (en) 1998-10-29 2003-03-20 Kosan Biosciences, Inc. Recombinant oleandolide polyketide synthase
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
DE69910831T2 (de) 1998-12-22 2004-07-15 Novartis Ag Epothilonderivate und ihre verwendung als antitumormittel
EP1140928A4 (en) 1998-12-23 2002-10-02 Bristol Myers Squibb Co MICROBIAL CONVERSION METHOD FOR PRODUCING AN EPOTHILONE
CA2360952A1 (en) 1999-02-11 2000-08-17 Schering Aktiengesellschaft Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
CN1209360C (zh) 1999-02-18 2005-07-06 舍林股份公司 16－卤－依泊昔酮衍生物、其制备方法及其医药用途
KR100685336B1 (ko) 1999-02-22 2007-02-23 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) Ｃ-21 변형 에포틸론
AU4017400A (en) 1999-03-29 2000-10-16 Bristol-Myers Squibb Company A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
AU773678B2 (en) 1999-04-16 2004-06-03 Kosan Biosciences, Inc. Macrolide antiinfective agents
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6268488B1 (en) 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
WO2001007439A2 (en) 1999-07-22 2001-02-01 Schering Aktiengesellschaft Process for the production of epothiolone b and derivatives as well as intermediate products for this process
HUP9902628A3 (en) 1999-08-02 2001-07-30 Ivax Gyogyszerki Kft Angiogenesis inhibiting borrelidin derivatives, their use and pharmaceutical compositions containing them
CA2425620A1 (en) 1999-10-08 2001-04-19 The Scripps Research Institute 13-alkyl epothilone derivatives
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
AU2003218110A1 (en) 2003-09-29
US6719540B2 (en) 2004-04-13
US20030191089A1 (en) 2003-10-09
EP1483251A1 (en) 2004-12-08
SI1483251T1 (sl) 2010-03-31
PT1483251E (pt) 2010-02-26
DK1483251T3 (da) 2010-04-12
EP1483251A4 (en) 2006-02-08
DE60330651D1 (en) 2010-02-04
EP1483251B1 (en) 2009-12-23
ATE452896T1 (de) 2010-01-15
ES2337134T3 (es) 2010-04-21
WO2003078411A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
ATE484508T1 (de) Furylverbindungen
SE0300119D0 (sv) Novel compounds
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
PE20041076A1 (es) Nuevas pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
PE20041000A1 (es) Pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
ATE433981T1 (de) Heterocyclische verbindungen
EP1615914A4 (en) CGRP RECEPTOR ANTAGONISTS
TW200745004A (en) Novel compounds, their preparation and use
DE60333746D1 (de) Thienylverbindungen
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
MY141583A (en) Novel fused heterocycles and uses thereof
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
SE0300091D0 (sv) Novel compounds
EP1794120A4 (en) peptidase
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
GEP20053590B (en) Phenyl Heterocyclyl Ether Derivatives as Serotonin Re-Uptake Inhibitors
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
BRPI0411867A (pt) tiofenilaminoimidazolinas
MXPA05004845A (es) N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.
DE60224509D1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
MXPA05006530A (es) Derivados de 1-n-fenilamino-1h-imidazola como inhibidores aromatasa.